Clene seeks accelerated FDA approval for CNM‑Au8 while facing $7.3M cash, mounting losses

Clene Inc. (NASDAQ: CLNN) - quick read on what's happening inside the company and the income statement (figures as reported, in thousands unless noted).

Snapshot

- Cash and cash equivalents (June 30, 2025): $7,285

- Total assets: $22,125

- Total liabilities: $30,675

- Stockholders' deficit: $(8,550)

- Shares issued and outstanding (June 30, 2025): 9,462,071

Income statement - key numbers (Three months ended June 30, 2025)

- Total revenue: $27

- Product revenue (Q2): $1

- Royalty revenue (Q2): $26

- Research & development expense (Q2): $3,514

- General & administrative expense (Q2): $2,377

- Total operating expenses (Q2): $5,891

- Loss from operations (Q2): $(5,864)

- Total other expense, net (Q2): $(1,555)

- Net loss (Q2): $(7,419)

- Net loss per share - basic & diluted (Q2): $(0.78)

Year-to-date (Six months ended June 30, 2025) highlights

- Total revenue YTD: $108

- Net loss YTD: $(8,170)

- Loss per share YTD: $(0.89)

- Net cash used in operating activities YTD: $(9,755)

- Accumulated deficit (June 30, 2025): $(290,293)

What's happening inside the company - operational & regulatory

- FDA engagement: Division of Neurology 1 gave guidance on potential accelerated approval path for CNM-Au8 in ALS; company plans NDA submission by end of 2025 if EAP NfL data align with prior trial results.

- Clinical programs: planning RESTORE‑ALS (Phase 3) for H1 2026 (contingent on funding); REPAIR‑MS second dosing cohort enrolled (topline expected Q3 2025).

- Grants: NIH ACT‑EAP funding drives reimbursable grant revenue (recognized as reductions to R&D) - $6,225 recorded as reduction to R&D for six months ended June 30, 2025.

- Cost actions: company implemented cost-saving measures (hiring freeze, reduced compensation, program delays) and reduced R&D and G&A versus prior periods.

- Financing activity: equity ATM proceeds during period $5,100 (gross) YTD; subsequent post‑period ATM $1,900 (gross); issued $1.5M of senior secured convertible notes (Aug 2025 event noted in filing).

- Governance / controls: management disclosed material weaknesses in internal control (reconciliations, manual journal entries, IT general controls); remediation ongoing.

Positive aspects of the income statement / financials

- Operating expense reductions: R&D down 50% YTD (4,995 vs. 10,019) and G&A down 25% YTD (5,033 vs. 6,734) versus prior year six‑month periods, reflecting cost discipline.

- Grant offsets: substantial grant recognition reduced R&D by $6,225 YTD, materially lowering cash R&D burden.

- Non‑cash accounting benefits: favorable fair value movement of certain warrant/derivative items produced a $1,995 gain in the six months ended June 30, 2025 (recorded in other income), partially offsetting cash losses.

- Active capital raising: ATM and private note activity produced multiple inflows in 2025 (gross ATM proceeds $5.1M YTD + subsequent $1.9M; additional note financings post‑period), showing access to capital markets.

Negative aspects of the income statement / financials

- Revenue negligible and declining: total revenue Q2 $27 (down 70% YoY); dependence on related‑party supplement sales and royalties (4Life) - no product drug revenue.

- Continued losses and cash burn: Q2 net loss $(7,419); YTD operating cash burn $(9,755). Cash balance only $7,285 - runway constrained.

- Balance sheet stress: total liabilities $30,675 exceed assets $22,125; stockholders' deficit $(8,550).

- Heavy debt & derivative exposure: convertible notes payable $11,134; SSCP notes principal $10,000 (Dec 2024 issuance) with derivative features measured at fair value - volatility produces non‑cash swings in earnings; interest expense and high effective rates on convertible instruments.

- Going concern: management states substantial doubt about ability to continue beyond 12 months absent additional financing; covenant in SSCP notes requires maintaining at least $2.0M unrestricted cash.

- Control weaknesses: material weaknesses in financial reporting controls create execution and disclosure risk until remediated.

Other material statistics / items to note

- Common stock warrants outstanding: total shares underlying warrants 7,242,876 (various classes; many liability‑classified).

- Weighted average shares used for Q2 loss per share: 9,523,592.

- Change in warrant liabilities (Dec 31, 2024 → Jun 30, 2025): $4,541 → $2,546 (Level 3 fair value).

- Derivative liabilities (Dec 31, 2024 → Jun 30, 2025): $1,804 → $1,096.

What to watch next

- FDA Type C meeting outcomes and EAP NfL analyses (NDA timing & viability).
- REPAIR‑MS topline in Q3 2025.
- Near‑term cash runway and financing (ATM sales, further note financings, or partnerships) and compliance with SSCP cash covenant ($2.0M minimum).
- Remediation progress on internal control weaknesses (affects reporting reliability and investor confidence).

Bottom line

- Clene is advancing clinical/regulatory work (notably FDA engagement on accelerated approval for CNM‑Au8) and has reduced operating expenses and used grants to offset R&D costs - but revenue remains trivial, cash is limited ($7.3M), liabilities exceed assets, convertible debt and warrant/derivative volatility create earnings swings, and management warns of substantial doubt about going concern without additional financing. Key near‑term catalysts (EAP NfL data, NDA decision, MS topline, and financing) will determine whether the company can fund its path to potential approval.